Cristyn Davies1,2, Melody Taba1,2, Lucy Deng1,3, Ceylan Karatas1,4, Shopna Bag5,6, Charles Ross7, Angus Forster7, Robert Booy1,2, S Rachel Skinner1,2. 1. Specialty of Child and Adolescent Health, The Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia. 2. Sydney Institute of Infectious Diseases, University of Sydney, Sydney, Australia. 3. National Centre for Immunisation Research and Surveillance, The Children's Hospital at Westmead, Westmead, Australia. 4. Graduate School of Medicine, The University of Wollongong, Keiraville, Australia. 5. Centre for Population Health, Western Sydney Public Health Unit, North Parramatta, Australia. 6. Faculty of Medicine and Health, Westmead Clinical School, The University of Sydney, Westmead, Australia. 7. Vaxxas Pty Ltd, Translational Research Institute, Woolloongabba, Australia.
Abstract
BACKGROUND: High-density microarray patch (HD-MAP) vaccines may increase vaccine acceptance and use. We aimed to ascertain whether professional immunizers (PIs) and other healthcare workers (HCWs) in Australia, a High-Income Country (HIC), found the HD-MAP applicator usable and acceptable for vaccine delivery. METHODS: This feasibility study recruited PIs and HCWs to administer/receive simulated HD-MAP administration, including via self-administration. We assessed usability against essential and desirable criteria. Participants completed a survey, rating their agreement to statements about HD-MAP administration. A subset also participated in an interview or focus group. Survey data were analyzed using descriptive statistics, and interviews were transcribed and subject to thematic analysis. RESULTS: We recruited 61 participants: 23 PIs and 38 HCWs. Findings indicated high usability and acceptability of HD-MAP use across both groups by a healthcare professional or trained user and for self-administration with safety measures in place. Most administrations met essential criteria, but PIs, on average, applied the HD-MAP for slightly less time than the required 10-seconds, which the HCWs achieved. PIs perceived safety concerns about home administration but found layperson self-administration acceptable in an emergency, pandemic, and rural or remote settings. CONCLUSIONS: Participants found HD-MAP administration usable and acceptable. Usability and acceptability are likely to be improved through end-user education and training.
BACKGROUND: High-density microarray patch (HD-MAP) vaccines may increase vaccine acceptance and use. We aimed to ascertain whether professional immunizers (PIs) and other healthcare workers (HCWs) in Australia, a High-Income Country (HIC), found the HD-MAP applicator usable and acceptable for vaccine delivery. METHODS: This feasibility study recruited PIs and HCWs to administer/receive simulated HD-MAP administration, including via self-administration. We assessed usability against essential and desirable criteria. Participants completed a survey, rating their agreement to statements about HD-MAP administration. A subset also participated in an interview or focus group. Survey data were analyzed using descriptive statistics, and interviews were transcribed and subject to thematic analysis. RESULTS: We recruited 61 participants: 23 PIs and 38 HCWs. Findings indicated high usability and acceptability of HD-MAP use across both groups by a healthcare professional or trained user and for self-administration with safety measures in place. Most administrations met essential criteria, but PIs, on average, applied the HD-MAP for slightly less time than the required 10-seconds, which the HCWs achieved. PIs perceived safety concerns about home administration but found layperson self-administration acceptable in an emergency, pandemic, and rural or remote settings. CONCLUSIONS: Participants found HD-MAP administration usable and acceptable. Usability and acceptability are likely to be improved through end-user education and training.
Authors: Matthew Z Dudley; Neal A Halsey; Saad B Omer; Walter A Orenstein; Sean T O'Leary; Rupali J Limaye; Daniel A Salmon Journal: Lancet Infect Dis Date: 2020-04-09 Impact factor: 25.071
Authors: Germain J P Fernando; Julian Hickling; Cesar M Jayashi Flores; Paul Griffin; Christopher D Anderson; S Rachel Skinner; Cristyn Davies; Katey Witham; Melinda Pryor; Jesse Bodle; Steve Rockman; Ian H Frazer; Angus H Forster Journal: Vaccine Date: 2018-05-17 Impact factor: 3.641
Authors: Paula M Frew; Michele Bennett Paine; Nadine Rouphael; Jay Schamel; Yunmi Chung; Mark J Mulligan; Mark R Prausnitz Journal: Vaccine Date: 2020-08-10 Impact factor: 3.641
Authors: James J Norman; Jaya M Arya; Maxine A McClain; Paula M Frew; Martin I Meltzer; Mark R Prausnitz Journal: Vaccine Date: 2014-02-11 Impact factor: 3.641
Authors: Cristyn Davies; Helen S Marshall; Gregory Zimet; Kirsten McCaffery; Julia M L Brotherton; Melissa Kang; Suzanne Garland; John Kaldor; Kevin McGeechan; S Rachel Skinner Journal: JAMA Netw Open Date: 2021-11-01
Authors: Fredrik Iredahl; David A Muller; Totte Togö; Hanna Jonasson; Ben Baker; Chris D Anderson; Joakim Henricson Journal: Vaccines (Basel) Date: 2022-04-10